NO331906B1 - Dispersjonsformuleringer inneholdende lipaseinhibitorer, fremgangsmate for fremstilling av slike samt anvendelse av slike for forebygging og behandling av fedme. - Google Patents
Dispersjonsformuleringer inneholdende lipaseinhibitorer, fremgangsmate for fremstilling av slike samt anvendelse av slike for forebygging og behandling av fedme. Download PDFInfo
- Publication number
- NO331906B1 NO331906B1 NO20021204A NO20021204A NO331906B1 NO 331906 B1 NO331906 B1 NO 331906B1 NO 20021204 A NO20021204 A NO 20021204A NO 20021204 A NO20021204 A NO 20021204A NO 331906 B1 NO331906 B1 NO 331906B1
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical preparation
- preparation according
- dispersant
- total weight
- mixtures
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 59
- 239000000203 mixture Substances 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 11
- 208000008589 Obesity Diseases 0.000 title claims description 6
- 235000020824 obesity Nutrition 0.000 title claims description 6
- 230000002265 prevention Effects 0.000 title claims description 6
- 229940127470 Lipase Inhibitors Drugs 0.000 title description 8
- 239000006185 dispersion Substances 0.000 title description 4
- 238000009472 formulation Methods 0.000 title 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 34
- 229960001243 orlistat Drugs 0.000 claims abstract description 32
- 239000002270 dispersing agent Substances 0.000 claims abstract description 27
- 239000004094 surface-active agent Substances 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 15
- 108090001060 Lipase Proteins 0.000 claims abstract description 14
- 102000004882 Lipase Human genes 0.000 claims abstract description 14
- 239000004367 Lipase Substances 0.000 claims abstract description 14
- 235000019421 lipase Nutrition 0.000 claims abstract description 14
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 102000019280 Pancreatic lipases Human genes 0.000 claims abstract description 6
- 108050006759 Pancreatic lipases Proteins 0.000 claims abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 30
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 16
- -1 diglycerides Chemical class 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 150000003626 triacylglycerols Chemical class 0.000 claims description 10
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000001087 glyceryl triacetate Substances 0.000 claims description 4
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- 229960002622 triacetin Drugs 0.000 claims description 4
- 230000036760 body temperature Effects 0.000 claims description 3
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000004064 cosurfactant Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 11
- 235000012054 meals Nutrition 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000005456 glyceride group Chemical group 0.000 description 5
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 101001064310 Rattus norvegicus Gastric triacylglycerol lipase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000946767 Streptomyces toxytricini Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000012020 french fries Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940074049 glyceryl dilaurate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940068939 glyceryl monolaurate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000892 gravimetry Methods 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99118180 | 1999-09-13 | ||
| PCT/EP2000/008858 WO2001019340A1 (fr) | 1999-09-13 | 2000-09-11 | Preparations de dispersion contenant des inhibiteurs de lipases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20021204D0 NO20021204D0 (no) | 2002-03-12 |
| NO20021204L NO20021204L (no) | 2002-03-12 |
| NO331906B1 true NO331906B1 (no) | 2012-04-30 |
Family
ID=8238990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20021204A NO331906B1 (no) | 1999-09-13 | 2002-03-12 | Dispersjonsformuleringer inneholdende lipaseinhibitorer, fremgangsmate for fremstilling av slike samt anvendelse av slike for forebygging og behandling av fedme. |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20030181512A1 (fr) |
| EP (1) | EP1216025B1 (fr) |
| JP (1) | JP4217016B2 (fr) |
| KR (1) | KR100572434B1 (fr) |
| CN (1) | CN1197551C (fr) |
| AR (1) | AR025587A1 (fr) |
| AT (1) | ATE333866T1 (fr) |
| AU (1) | AU769415B2 (fr) |
| BR (2) | BRPI0013939B1 (fr) |
| CA (1) | CA2383916C (fr) |
| CO (1) | CO5180587A1 (fr) |
| CY (1) | CY1106180T1 (fr) |
| CZ (1) | CZ301901B6 (fr) |
| DE (1) | DE60029602T2 (fr) |
| DK (1) | DK1216025T3 (fr) |
| EG (1) | EG24117A (fr) |
| ES (1) | ES2267563T3 (fr) |
| HR (1) | HRP20020205B1 (fr) |
| HU (1) | HU228858B1 (fr) |
| IL (1) | IL148494A0 (fr) |
| JO (1) | JO2386B1 (fr) |
| MA (1) | MA26818A1 (fr) |
| ME (1) | MEP90808A (fr) |
| MX (1) | MXPA02002034A (fr) |
| MY (1) | MY130200A (fr) |
| NO (1) | NO331906B1 (fr) |
| NZ (1) | NZ517545A (fr) |
| PE (1) | PE20010595A1 (fr) |
| PL (1) | PL199870B1 (fr) |
| PT (1) | PT1216025E (fr) |
| RS (1) | RS50422B (fr) |
| RU (1) | RU2239428C2 (fr) |
| SI (1) | SI1216025T1 (fr) |
| TR (1) | TR200200606T2 (fr) |
| TW (1) | TWI243060B (fr) |
| UY (1) | UY26338A1 (fr) |
| WO (1) | WO2001019340A1 (fr) |
| ZA (1) | ZA200201518B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20030029B1 (en) * | 2000-07-28 | 2005-06-30 | F. Hoffmann - La Roche Ag | New pharmaceutical composition |
| US6730319B2 (en) * | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| US8372430B2 (en) * | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| FI20045076A7 (fi) * | 2004-03-15 | 2005-09-16 | Bioferme Oy | Funktionaalinen elintarvike |
| DK2985026T3 (da) * | 2005-04-15 | 2022-10-31 | Clarus Therapeutics Inc | Farmaceutiske leveringssystemer til hydrofobe lægemidler og sammensætninger dermed |
| KR100910000B1 (ko) * | 2005-05-13 | 2009-07-29 | 씨제이제일제당 (주) | 리파아제 저해제 함유 약학 조성물 |
| ES2434072T3 (es) * | 2005-06-09 | 2013-12-13 | Norgine Bv | Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona |
| KR100669497B1 (ko) * | 2005-08-17 | 2007-01-16 | 보람제약주식회사 | 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법 |
| WO2007033522A1 (fr) * | 2005-09-21 | 2007-03-29 | Shenzhen Tys R & D Co., Ltd. | Formulation de gélule contenant de la moxifloxacine et son procédé de préparation |
| KR101252635B1 (ko) | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
| TR200607613A2 (tr) * | 2006-12-29 | 2008-07-21 | NOBEL İLAÇ SAN.ve TiC.A.Ş. | Lipaz inhibitörü içeren farmasötik formülasyonlar |
| EP1970051A1 (fr) * | 2007-03-14 | 2008-09-17 | Merz Pharma GmbH & Co.KGaA | Utilisation d'une micro-émulsion aqueuse pour la préparation d'une formulation pour le traitement de maladies adipeuses |
| KR101439470B1 (ko) * | 2007-05-22 | 2014-09-16 | 한미사이언스 주식회사 | 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물 |
| EP2036575B1 (fr) * | 2007-09-12 | 2010-08-18 | Mader S.r.l. | Compositions pharmaceutiques à administration orale pour traiter des patients touchés par l'obésité |
| EP2044930A1 (fr) * | 2007-10-01 | 2009-04-08 | Nestec S.A. | Composition pour le contrôle de réactions catalysées par la lipase |
| PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
| WO2010042499A1 (fr) * | 2008-10-06 | 2010-04-15 | Banner Pharmacaps, Inc. | Solutions stables d'orlistat pour formes galéniques pharmaceutiques |
| KR20100075260A (ko) * | 2008-12-24 | 2010-07-02 | 주식회사종근당 | 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물 |
| BRPI0901602B8 (pt) | 2009-04-03 | 2021-05-25 | Ems S/A | formulação farmacêuticas |
| RU2441654C2 (ru) * | 2010-02-17 | 2012-02-10 | Лабораториос Баго С.А. | Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| BR112017021995A2 (pt) * | 2015-04-14 | 2018-07-10 | Zim Laboratories Ltd | formulação farmacêutica compreendendo drogas de baixa fusão e altamente lipofílicas e método de melhora da dissolução |
| CN106310287B (zh) * | 2015-06-25 | 2019-03-19 | 山东省药学科学院 | 新利司他药用组合物及其制备方法 |
| MY196635A (en) * | 2018-06-22 | 2023-04-25 | Sime Darby Plantation Intellectual Property Sdn Bhd | Method For Reducing Formation of Free Fatty Acids in Plants |
| CN115105476B (zh) * | 2021-03-23 | 2023-11-14 | 山东新时代药业有限公司 | 一种奥利司他冻干口服制剂及其制备工艺 |
| CN114983938A (zh) * | 2022-05-19 | 2022-09-02 | 广东嘉博制药有限公司 | 一种奥利司他口服复合乳液及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (fr) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Derives de leucine |
| DE3887179T2 (de) * | 1987-03-02 | 1994-06-16 | Brocades Pharma Bv | Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung. |
| SU1510148A1 (ru) * | 1988-01-26 | 1995-04-30 | Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств | Способ получения ингибитора липазы |
| CA2128044C (fr) | 1993-08-05 | 2007-02-20 | Klaus-Dieter Bremer | Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases |
| IT1282673B1 (it) | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
| US5891469A (en) * | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| JP2001523221A (ja) | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| NZ336755A (en) * | 1997-02-05 | 2001-06-29 | F | Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat) |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| CN1170534C (zh) | 1998-08-14 | 2004-10-13 | 霍夫曼-拉罗奇有限公司 | 含有脂酶抑制剂的药物组合物 |
| JP3761783B2 (ja) | 1998-08-14 | 2006-03-29 | エフ．ホフマン−ラ ロシュ アーゲー | リパーゼ阻害剤とキトサンを含む製薬学的組成物 |
| US6368622B2 (en) * | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
-
2000
- 2000-09-07 AR ARP000104679A patent/AR025587A1/es not_active Application Discontinuation
- 2000-09-11 KR KR1020027003269A patent/KR100572434B1/ko not_active Expired - Lifetime
- 2000-09-11 BR BRPI0013939-4A patent/BRPI0013939B1/pt unknown
- 2000-09-11 HU HU0202737A patent/HU228858B1/hu unknown
- 2000-09-11 IL IL14849400A patent/IL148494A0/xx active IP Right Grant
- 2000-09-11 RU RU2002107428/15A patent/RU2239428C2/ru active
- 2000-09-11 ES ES00960643T patent/ES2267563T3/es not_active Expired - Lifetime
- 2000-09-11 EP EP00960643A patent/EP1216025B1/fr not_active Expired - Lifetime
- 2000-09-11 DK DK00960643T patent/DK1216025T3/da active
- 2000-09-11 CA CA002383916A patent/CA2383916C/fr not_active Expired - Lifetime
- 2000-09-11 NZ NZ517545A patent/NZ517545A/en not_active IP Right Cessation
- 2000-09-11 TR TR2002/00606T patent/TR200200606T2/xx unknown
- 2000-09-11 SI SI200030888T patent/SI1216025T1/sl unknown
- 2000-09-11 CZ CZ20021276A patent/CZ301901B6/cs not_active IP Right Cessation
- 2000-09-11 PT PT00960643T patent/PT1216025E/pt unknown
- 2000-09-11 JP JP2001522975A patent/JP4217016B2/ja not_active Expired - Lifetime
- 2000-09-11 WO PCT/EP2000/008858 patent/WO2001019340A1/fr not_active Ceased
- 2000-09-11 BR BR0013939-4A patent/BR0013939A/pt not_active IP Right Cessation
- 2000-09-11 RS YUP-172/02A patent/RS50422B/sr unknown
- 2000-09-11 HR HR20020205A patent/HRP20020205B1/xx not_active IP Right Cessation
- 2000-09-11 AU AU72863/00A patent/AU769415B2/en not_active Expired
- 2000-09-11 MX MXPA02002034A patent/MXPA02002034A/es active IP Right Grant
- 2000-09-11 CN CNB008126801A patent/CN1197551C/zh not_active Expired - Lifetime
- 2000-09-11 PL PL356174A patent/PL199870B1/pl unknown
- 2000-09-11 DE DE60029602T patent/DE60029602T2/de not_active Expired - Lifetime
- 2000-09-11 ME MEP-908/08A patent/MEP90808A/xx unknown
- 2000-09-11 AT AT00960643T patent/ATE333866T1/de active
- 2000-09-12 CO CO00068859A patent/CO5180587A1/es active IP Right Grant
- 2000-09-12 JO JO2000157A patent/JO2386B1/en active
- 2000-09-12 UY UY26338A patent/UY26338A1/es not_active Application Discontinuation
- 2000-09-12 EG EG20001159A patent/EG24117A/xx active
- 2000-09-13 PE PE2000000949A patent/PE20010595A1/es not_active IP Right Cessation
- 2000-09-13 MY MYPI20004253A patent/MY130200A/en unknown
- 2000-10-19 TW TW089121968A patent/TWI243060B/zh not_active IP Right Cessation
-
2002
- 2002-02-22 ZA ZA200201518A patent/ZA200201518B/xx unknown
- 2002-03-11 MA MA26545A patent/MA26818A1/fr unknown
- 2002-03-12 NO NO20021204A patent/NO331906B1/no not_active IP Right Cessation
-
2003
- 2003-04-21 US US10/419,346 patent/US20030181512A1/en not_active Abandoned
-
2004
- 2004-03-05 US US10/794,123 patent/US8012494B2/en not_active Expired - Lifetime
-
2006
- 2006-09-29 CY CY20061101416T patent/CY1106180T1/el unknown
-
2011
- 2011-07-19 US US13/185,558 patent/US20110275706A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331906B1 (no) | Dispersjonsformuleringer inneholdende lipaseinhibitorer, fremgangsmate for fremstilling av slike samt anvendelse av slike for forebygging og behandling av fedme. | |
| KR100880859B1 (ko) | 자발분산성 ｎ-벤조일-스타우로스포린 조성물 | |
| US20110301231A1 (en) | Lipase inhibiting composition | |
| AU2002257817A1 (en) | Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester | |
| KR101928589B1 (ko) | 알리스포리비르를 포함하는 제약 조성물 | |
| HK1049966B (en) | Dispersion formulations containing lipase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |